WHO预认证是一个动态、持续监管的过程，而非一次性的资格授予。此次对大连科兴的现场复审，是WHO对科兴水痘减 毒活疫苗自2022年11月份成功通过预认证后所进行的首次全面再评估。来自WHO的国际专家检查团对大连科兴的质量管理体 系、生产车间设计与维护、产品全生命周期管理等方面进行了系统、全面、严格的审核。 本报讯 （记者张敏）12月17日，记者从北京科兴控股（集团）有限公司（以下简称"科兴集团"）获悉，近日，该公司旗下 科兴（大连）疫苗技术有限公司（以下简称"大连科兴"）生产的水痘减毒活疫苗顺利通过了世界卫生组织（WHO）预认证复 审。这标志着大连科兴在疫苗质量管理、生产体系建设以及国际标准规范方面再次获得权威认可，为持续提升高品质水痘疫苗 的全球可及性奠定了坚实基础。 （编辑 黄力） 记者从科兴集团获悉，大连科兴的水痘疫苗对于环境要求及控制极高，是国内唯一在全程B+A高洁净度环境下生产的水痘 疫苗，极大地控制了污染风险，提高了产品品质。截至目前，科兴集团甲型肝炎灭活疫苗（孩尔来福®）、水痘减毒活疫苗和 Sabin株脊髓灰质炎灭活疫苗三款产品已先后获得WHO预认证。其中，科兴集团的水痘减毒活疫苗是国内首个且唯 ...

Core Viewpoint - The company, Sinovac Biotech, is facing a delisting crisis from NASDAQ due to its failure to submit the 2024 annual report on time, which has raised concerns about its future as a publicly traded entity [2][3]. Group 1: Delisting Crisis - Sinovac received a delisting notice from NASDAQ on November 12, 2025, after failing to submit its annual report by the deadline [2]. - The company has been suspended from trading since 2019 due to governance issues and is now facing a second delisting threat [2][3]. - Sinovac has hired a new auditing firm, UHY LLP, and plans to apply for a hearing to delay the delisting process, asserting that its core business remains unaffected [2][3]. Group 2: Governance Issues - The company has a history of governance problems, stemming from a power struggle between its founders, Yin Weidong and Pan Aihua, which has led to significant internal conflicts [3][4]. - The governance issues peaked in 2018, resulting in chaotic management practices, including attempts to dilute each other's shares [4][5]. Group 3: Financial Performance - Sinovac experienced a significant financial boost during the COVID-19 pandemic, reporting a net profit of $8.46 billion in 2021 [5]. - However, the company has faced declining revenues from its COVID-19 vaccine, leading to a reported net loss of $258 million in 2023 [7][8]. - The company has a substantial cash reserve of $10.3 billion, which has become a focal point in the ongoing power struggle among shareholders [6][7]. Group 4: Dividend Controversy - Sinovac announced a controversial dividend plan totaling $7.448 billion, which raised concerns given its current market capitalization of only $389 million [6][7]. - The dividend plan is seen as a way to compensate shareholders for the lack of liquidity due to the stock suspension [7]. Group 5: Ongoing Internal Conflicts - The company is currently experiencing intense boardroom battles, with a recent special shareholder meeting resulting in the removal of the existing board and the return of founder Yin Weidong [8][9]. - The legitimacy of the special meeting has been challenged by the current chairman, Li Jiaqiang, citing a court injunction [9].